Selecting Patients for Treatment with CO-1686

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.

Clinical Pearls:

  • The vast majority of patients with newly diagnosed lung cancer have an analysis of their EGFR genes looking for the activating mutations.
  • This is done on tissue using PCR testing.
  • Clovis Oncology uses a tissue-based T790M detection test for the identification of appropriate patients in clinical trials involving CO-1686.
  • While there is a lot of interest in plasma as a way of detecting mutations in patients, it is not yet replacing tissue-based testing.​